Forum Financial Management LP Acquires New Position in Natera, Inc. (NASDAQ:NTRA)

Forum Financial Management LP bought a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,065 shares of the medical research company's stock, valued at approximately $327,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. increased its position in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares in the last quarter. Principal Securities Inc. increased its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in shares of Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after acquiring an additional 332 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on NTRA. StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. Sanford C. Bernstein boosted their target price on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, January 10th. Barclays dropped their target price on shares of Natera from $200.00 to $160.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Royal Bank of Canada began coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price on the stock. Finally, Piper Sandler boosted their target price on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $175.76.

Natera Price Performance

Shares of NTRA traded down $0.69 during midday trading on Friday, reaching $153.79. The stock had a trading volume of 806,949 shares, compared to its average volume of 1,383,185. The company's 50-day moving average is $147.95 and its 200 day moving average is $153.71. Natera, Inc. has a 12-month low of $90.88 and a 12-month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $20.79 billion, a price-to-earnings ratio of -87.38 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Activity at Natera

In other Natera news, insider John Fesko sold 663 shares of the business's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. The trade was a 0.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 5,201 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total value of $862,689.87. Following the sale, the insider now owns 135,483 shares of the company's stock, valued at approximately $22,472,565.21. This represents a 3.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 198,743 shares of company stock valued at $30,558,447 in the last 90 days. Corporate insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.